Stephen Westaby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephen Westaby has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Satoshi Saito
10 shared publicationsTakahiro Katsumata
8 shared publications- Adrian Paul Banning
Oxford Heart Center, Oxford University Hospitals NHS Foundation Trust, United Kingdom (A.P.B.).
5 shared publications Desiree Robson
4 shared publicationsRobert Jarvik
4 shared publicationsKyriakos Anastasiadis
Cardiothoracic Department, AHEPA University Hospital, Thessaloniki, Greece
3 shared publications
Latest Publications
- 1 September 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34  (9) , 1208-1210
Evidence for neoangiogenesis in the ischemic human heart after mechanical support and autologous bone marrow stem cell implantation
- 1 September 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34  (9) , 1208-1210
Evidence for neoangiogenesis in the ischemic human heart after mechanical support and autologous bone marrow stem cell implantation
- Open Access
- 4 July 2015
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 49  (3) , 1019-20
Reply to West.
We thank the author for his response but we enforce the fact that our methodology was robust [ 1 , 2 ]. We deliberately chose to avoid competition ratio data, which are known to be ‘open to confounding’. West [ 1 ] states ‘In 2014 the ratio was 10.3 applicants per post, the highest ratio for any specialty’. In fact, the highest competition ratio was for maxillofacial surgery at 21.8 applicants per post [ 3 ]. West uses competition ratio data to support his belief that ‘cardiothoracic surgery remains a highly sought-after career’ but fails to discuss the pitfalls of this method. Alison Carr of the UK Medical and Dental Recruitment and Selection Careers Planning Group has stated ‘competition ratios must never be viewed in isolation. They would be accurate as indicators of popularity only if applicants applied to one specialty [ 4 ]. They must be understood in the context of applicants making multiple applications to different specialities’ [ 4 ]. To assess competition reliably requires knowledge of the number of unique applicants to a specialty in comparison with the number of posts available, also taking into account the number of other specialties the applicants have applied for [ 5 ]. Indeed, West avoids the issue that in 2014 most cardiothoracic candidates applied for several other specialties ranging from public health, general practice, ophthalmology, neurosurgery and community and reproductive sexual health [ 3 ]. Far from being the most sought-after specialty, cardiothoracic surgery had the lowest proportion of unique applicants. Only 13 (18.1%) applied just for cardiothoracic surgery resulting in a meagre competition ratio of 1.86 (13 applicants for 7 posts). In turn, Carr et al. reporting ‘Higher Surgical Training ST3’ competition ratios (2011) showed cardiothoracic surgery to be least popular with the lowest ratio (4.5) of all surgical specialties. Paediatric surgery, plastic surgery and trauma and orthopaedic surgery had the highest competition ratios, respectively [ 6 ].
- 4 July 2015
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 49  (3) , 1019-20
Open AccessReply to West.
We thank the author for his response but we enforce the fact that our methodology was robust [ 1 , 2 ]. We deliberately chose to avoid competition ratio data, which are known to be ‘open to confounding’. West [ 1 ] states ‘In 2014 the ratio was 10.3 applicants per post, the highest ratio for any specialty’. In fact, the highest competition ratio was for maxillofacial surgery at 21.8 applicants per post [ 3 ]. West uses competition ratio data to support his belief that ‘cardiothoracic surgery remains a highly sought-after career’ but fails to discuss the pitfalls of this method. Alison Carr of the UK Medical and Dental Recruitment and Selection Careers Planning Group has stated ‘competition ratios must never be viewed in isolation. They would be accurate as indicators of popularity only if applicants applied to one specialty [ 4 ]. They must be understood in the context of applicants making multiple applications to different specialities’ [ 4 ]. To assess competition reliably requires knowledge of the number of unique applicants to a specialty in comparison with the number of posts available, also taking into account the number of other specialties the applicants have applied for [ 5 ]. Indeed, West avoids the issue that in 2014 most cardiothoracic candidates applied for several other specialties ranging from public health, general practice, ophthalmology, neurosurgery and community and reproductive sexual health [ 3 ]. Far from being the most sought-after specialty, cardiothoracic surgery had the lowest proportion of unique applicants. Only 13 (18.1%) applied just for cardiothoracic surgery resulting in a meagre competition ratio of 1.86 (13 applicants for 7 posts). In turn, Carr et al. reporting ‘Higher Surgical Training ST3’ competition ratios (2011) showed cardiothoracic surgery to be least popular with the lowest ratio (4.5) of all surgical specialties. Paediatric surgery, plastic surgery and trauma and orthopaedic surgery had the highest competition ratios, respectively [ 6 ].
- 1 April 2015
- Published by Royal College of Surgeons of England in The Bulletin of the Royal College of Surgeons of England
- Vol. 97  (4) , 155-159
Publishing SSMD: the risks outweigh the benefits
- 1 April 2015
- Published by Royal College of Surgeons of England in The Bulletin of the Royal College of Surgeons of England
- Vol. 97  (4) , 155-159
Publishing SSMD: the risks outweigh the benefits
- Open Access
- 29 October 2014
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 47  (2) , 341-345
Surgeon-specific mortality data disguise wider failings in delivery of safe surgical services
Feedback of clinical outcome data to clinicians can promote and enhance patient safety. Surgeon-specific mortality data (SSMD) have been released to the public for a number of specialties. This implies that one individual is culpable for all deaths. Debate continues about SSMD because of risk-averse behaviour. In the USA, improved outcome measures derived from phase of care mortality analysis (POCMA) and the failure to rescue (FTR) are replacing SSMD, but they have not been tested in Europe. Using POCMA and FTR analysis, we studied hospital deaths in 1558 cardiac surgical patients between 2009 and 2013. Comorbidity and urgency status were used to calculate modified logistic EuroSCORE (MLE). The circumstances of death were critically reviewed by a panel of four experienced surgeons. Death certificate information and autopsy were taken into account. Deaths were then classified: Class 1 surgeon dependent, Class 2 FTR or Class 3 where multiple factors conspired to cause death. There were 51 deaths providing 3.3% mortality, as predicted by MLE. In the 86% who underwent autopsy, no surgical error was identified. Most deaths in each group were related to high-risk status, age, frailty, comorbidity and urgency. FTR was the predominant factor occurring in 45%. Though difficult operations were implicated in 37%, no deaths occurred in the operating theatre. Some FTR deaths occurred in low-risk patients. Scrutiny of FTR deaths provided important information that could be used for quality improvement. The study showed that most deaths cannot be prevented by the operating surgeon. They occurred through issues of patient comorbidity, lack of process or infrastructure. This casts doubt on SSMD publication alone as a tool for quality improvement. In contrast, POCMA and FTR highlight problems of process, and are more likely to promote advances in surgical care.
- 29 October 2014
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 47  (2) , 341-345
Open AccessSurgeon-specific mortality data disguise wider failings in delivery of safe surgical services
Feedback of clinical outcome data to clinicians can promote and enhance patient safety. Surgeon-specific mortality data (SSMD) have been released to the public for a number of specialties. This implies that one individual is culpable for all deaths. Debate continues about SSMD because of risk-averse behaviour. In the USA, improved outcome measures derived from phase of care mortality analysis (POCMA) and the failure to rescue (FTR) are replacing SSMD, but they have not been tested in Europe. Using POCMA and FTR analysis, we studied hospital deaths in 1558 cardiac surgical patients between 2009 and 2013. Comorbidity and urgency status were used to calculate modified logistic EuroSCORE (MLE). The circumstances of death were critically reviewed by a panel of four experienced surgeons. Death certificate information and autopsy were taken into account. Deaths were then classified: Class 1 surgeon dependent, Class 2 FTR or Class 3 where multiple factors conspired to cause death. There were 51 deaths providing 3.3% mortality, as predicted by MLE. In the 86% who underwent autopsy, no surgical error was identified. Most deaths in each group were related to high-risk status, age, frailty, comorbidity and urgency. FTR was the predominant factor occurring in 45%. Though difficult operations were implicated in 37%, no deaths occurred in the operating theatre. Some FTR deaths occurred in low-risk patients. Scrutiny of FTR deaths provided important information that could be used for quality improvement. The study showed that most deaths cannot be prevented by the operating surgeon. They occurred through issues of patient comorbidity, lack of process or infrastructure. This casts doubt on SSMD publication alone as a tool for quality improvement. In contrast, POCMA and FTR highlight problems of process, and are more likely to promote advances in surgical care.
Author's reply to Bolsin and Colson, Nelson and colleagues, and Vallance-Owen
I thank Bolsin and Colson, Nelson and colleagues, and Vallance-Owen for widening the debate on surgeon specific mortality data.1 2 3 4 Writing from Australia, Bolsin and Colson want to retain focus on surgeon culpability.2 Bolsin should have disclosed that he was the anaesthetist who triggered the Bristol Inquiry. For the sake of the profession as a whole …
Author's reply to Bolsin and Colson, Nelson and colleagues, and Vallance-Owen
I thank Bolsin and Colson, Nelson and colleagues, and Vallance-Owen for widening the debate on surgeon specific mortality data.1 2 3 4 Writing from Australia, Bolsin and Colson want to retain focus on surgeon culpability.2 Bolsin should have disclosed that he was the anaesthetist who triggered the Bristol Inquiry. For the sake of the profession as a whole …
- Open Access
- 18 March 2013
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 44  (3) , 425-6
Editorial comment: What really matters in aortic dissection?
Aortic dissection affects between 5 and 30 people per million population per year, while the incidence of acute myocardial infarction exceeds 4400 per million per year [1]. More than 70% of dissection patients are hypertensive before the event and 30% have pre-existing aneurysmal dilatation of the ascending aorta [2]. Many are misdiagnosed on initial evaluation, and around 30% are discovered at autopsy [3]. It can be difficult to differentiate between dissection and myocardial infarction on clinical history or initial findings and this delays surgical repair. Seventy percent of dissection patients have electrocardiographic changes and around 25% manifest troponin elevation [4]. For those with troponin elevation, 14% have ST segment elevation, 14% ST depression and 36% T-wave inversion. Though dissection commonly involves the coronary ostia, an additional mechanism for troponin release is haemodynamic stress through acute aortic regurgitation. Those with troponin elevation have a four times elevated risk of early death [3]. Information from the International Registry of Acute Aortic Dissection (IRAD) shows that 15% of patients suffer acute myocardial ischaemia through coronary malperfusion and 3% present with myocardial infarction [1]. As for primary myocardial infarction, these patients are likely to experience myocardial stunning with cardiogenic shock or prehospital cardiac arrest. The overall number with combined dissection plus acute myocardial infarction is probably underestimated, because they die before reaching the hospital.
- 18 March 2013
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 44  (3) , 425-6
Open AccessEditorial comment: What really matters in aortic dissection?
Aortic dissection affects between 5 and 30 people per million population per year, while the incidence of acute myocardial infarction exceeds 4400 per million per year [1]. More than 70% of dissection patients are hypertensive before the event and 30% have pre-existing aneurysmal dilatation of the ascending aorta [2]. Many are misdiagnosed on initial evaluation, and around 30% are discovered at autopsy [3]. It can be difficult to differentiate between dissection and myocardial infarction on clinical history or initial findings and this delays surgical repair. Seventy percent of dissection patients have electrocardiographic changes and around 25% manifest troponin elevation [4]. For those with troponin elevation, 14% have ST segment elevation, 14% ST depression and 36% T-wave inversion. Though dissection commonly involves the coronary ostia, an additional mechanism for troponin release is haemodynamic stress through acute aortic regurgitation. Those with troponin elevation have a four times elevated risk of early death [3]. Information from the International Registry of Acute Aortic Dissection (IRAD) shows that 15% of patients suffer acute myocardial ischaemia through coronary malperfusion and 3% present with myocardial infarction [1]. As for primary myocardial infarction, these patients are likely to experience myocardial stunning with cardiogenic shock or prehospital cardiac arrest. The overall number with combined dissection plus acute myocardial infarction is probably underestimated, because they die before reaching the hospital.
- 6 March 2013
- Published by Taylor & Francis in Future Cardiology
- Vol. 9  (2) , 199-213
Rotary Blood Pumps As Definitive Treatment for Severe Heart Failure
Rotary blood pumps are increasingly recognized as mainstream therapy for severely symptomatic heart failure. Carefully targeted refinements in patient selection and postoperative care have substantially reduced the adverse event burden. These improvements translate into better survival and quality of life in comparison with medical management. Medium-term outcomes now compete favorably with cardiac transplantation, although evidence-based outcome data indicate that transplant and 'lifetime' left ventricular-assist device (LVAD) candidates are fundamentally different. Significant challenges remain in relation to neurological injury and right heart failure, which may continue to limit exercise capacity. In the meantime, both physician awareness and patient access to LVAD technology remain limited. The debate is rarely between cardiac transplant or lifetime LVAD. It should focus on the choice between pump versus palliative care for the thousands of patients of all age groups who are judged ineligible for transplantation. Comprehensive healthcare systems must consider contemporary evidence and provide the most symptomatic of heart failure patients with effective care. Cardiac resynchronization therapy is no longer the ceiling for this.
- 6 March 2013
- Published by Taylor & Francis in Future Cardiology
- Vol. 9  (2) , 199-213
Rotary Blood Pumps As Definitive Treatment for Severe Heart Failure
Rotary blood pumps are increasingly recognized as mainstream therapy for severely symptomatic heart failure. Carefully targeted refinements in patient selection and postoperative care have substantially reduced the adverse event burden. These improvements translate into better survival and quality of life in comparison with medical management. Medium-term outcomes now compete favorably with cardiac transplantation, although evidence-based outcome data indicate that transplant and 'lifetime' left ventricular-assist device (LVAD) candidates are fundamentally different. Significant challenges remain in relation to neurological injury and right heart failure, which may continue to limit exercise capacity. In the meantime, both physician awareness and patient access to LVAD technology remain limited. The debate is rarely between cardiac transplant or lifetime LVAD. It should focus on the choice between pump versus palliative care for the thousands of patients of all age groups who are judged ineligible for transplantation. Comprehensive healthcare systems must consider contemporary evidence and provide the most symptomatic of heart failure patients with effective care. Cardiac resynchronization therapy is no longer the ceiling for this.
- 30 November 2012
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 38  (11) , 1130-1131
P93. TOE the line! Case report highlighting the importance of intraoperative TOE (transoesophageal echocardiography) monitoring when operating on renal cancers involving the right atrium
- 30 November 2012
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 38  (11) , 1130-1131
P93. TOE the line! Case report highlighting the importance of intraoperative TOE (transoesophageal echocardiography) monitoring when operating on renal cancers involving the right atrium
- Open Access
- 3 July 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42  (6) , 1033-1034
Editorial Comment: Multimodal intervention in the management of left ventricular assist device outpatients
Conflict of interest: Stephen Westaby is unpaid Medical Director of Calon Cardiotechnology.
- 3 July 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42  (6) , 1033-1034
Open AccessEditorial Comment: Multimodal intervention in the management of left ventricular assist device outpatients
Conflict of interest: Stephen Westaby is unpaid Medical Director of Calon Cardiotechnology.
- Open Access
- 30 May 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42  (2) , 203-208
Long-term biventricular support with rotary blood pumps: prospects and pitfalls
Congestive heart failure affects 23 million people worldwide, including 7.5 million in North America (670 000 new cases per year) and 7 million in Europe [1]. Since 10% of those over 65 suffer from systolic left ventricular dysfunction, the number of patients with heart failure will double over the next 25 years. At any time, 10% of the heart failure cohort are categorized Stage D with advanced structural heart disease and symptoms at rest, despite detailed medical and cardiac resynchronization therapy. Twenty percent of these are younger than 65 years of age (around 140 000 in both the USA and Europe).
- 30 May 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42  (2) , 203-208
Open AccessLong-term biventricular support with rotary blood pumps: prospects and pitfalls
Congestive heart failure affects 23 million people worldwide, including 7.5 million in North America (670 000 new cases per year) and 7 million in Europe [1]. Since 10% of those over 65 suffer from systolic left ventricular dysfunction, the number of patients with heart failure will double over the next 25 years. At any time, 10% of the heart failure cohort are categorized Stage D with advanced structural heart disease and symptoms at rest, despite detailed medical and cardiac resynchronization therapy. Twenty percent of these are younger than 65 years of age (around 140 000 in both the USA and Europe).